NCT05652907View on ClinicalTrials.gov

Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

May 24, 2023

Study Completion Date

May 24, 2023

Conditions
Mast Cell Activation SyndromeMast Cell Activation Disorder Idiopathic
Interventions
DRUG

FSD201

Tablets for oral administration.

DRUG

Placebo

Placebo tablets matched to FSD201 for oral administration.

Trial Locations (3)

10016

Norman Marcus Pain Institute, New York

63304

Saint Charles Clinical Research, Weldon Spring

Unknown

Toronto Rehabilitation Institute, Toronto

Sponsors

Lead Sponsor

Quantum Biopharma
All Listed Sponsors
lead

Quantum Biopharma

INDUSTRY

NCT05652907 - Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) | Biotech Hunter | Biotech Hunter